Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Aytu BioPharma, Inc. (AYTU) had Stock-Based Compensation of $0.55M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$12.41M |
|
$-5.62M |
|
$4.81M |
|
$7.60M |
|
$16.48M |
|
$-4.06M |
|
$-1.54M |
|
$-5.61M |
|
$-5.61M |
|
$-5.62M |
|
$-5.62M |
|
$-5.62M |
|
$-5.62M |
|
$-4.06M |
|
$-2.92M |
|
10.51M |
|
10.51M |
|
$-0.53 |
|
$-0.53 |
|
| Balance Sheet Financials | |
$67.33M |
|
$0.41M |
|
$44.36M |
|
$111.69M |
|
$59.97M |
|
$9.55M |
|
$16.57M |
|
$76.55M |
|
$35.14M |
|
$-7.35M |
|
$35.14M |
|
10.73M |
|
| Cash Flow Statement Financials | |
$-1.12M |
|
$-0.02M |
|
$-3.10M |
|
$30.95M |
|
$26.71M |
|
$-4.24M |
|
|
Stock-Based Compensation |
$0.55M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.12 |
|
-- |
|
-- |
|
0.21 |
|
0.62 |
|
61.23% |
|
-32.75% |
|
-32.75% |
|
-- |
|
-45.19% |
|
-45.27% |
|
$-1.14M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.65 |
|
0.51 |
|
177.59 |
|
-15.99% |
|
76.47% |
|
-5.03% |
|
-12.57% |
|
$3.27 |
|
$-0.11 |
|
$-0.11 |
|